Which companies are most active in acquisitions?

Eli Lilly, Johnson & Johnson, and Merck are among the active players.

How do these deals affect investors?

They signal confidence but carry integration risks.

Pharma and Biotech M&A Boom Accelerates in 2026

The pharmaceutical and biotech sectors are experiencing a surge in M&A activity in 2026, with major companies like Eli Lilly, Johnson & Johnson, and Merck aggressively acquiring to bolster their pipelines and portfolios.

June 11, 2026

2 min read

Source: Zacks

The pharmaceutical and biotech industry is witnessing a significant acceleration in merger and acquisition (M&A) activity in 2026, according to a report by Zacks. Major companies are pursuing acquisitions to expand their pipelines, strengthen portfolios, and drive growth.

Details

M&A activity in the pharma and biotech sectors is picking up pace this year. Companies such as Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck (MRK) are actively seeking to enhance their pipelines by acquiring promising startups with advanced technologies or late-stage drug candidates.

Context

This wave of deals comes as big pharma faces pressure to replace revenues lost to patent expirations on key drugs and to innovate in new therapeutic areas such as oncology and rare diseases.

What It Means for Investors

M&A activity signals confidence in the sector's future, but it also carries risks related to integration challenges and unmet expectations. Investors should monitor these deals and their impact on the companies' financial performance.

Frequently Asked Questions

Companies aim to replace revenues lost to patent expirations and to innovate in new therapeutic areas.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.